Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | CHRND | Q07001 | 7/20 | 0.47 |
| ▸ | GRIA1 | P42261 | 4/20 | 0.47 |
| ▸ | CHRNA1 | P02708 | 3/20 | 0.47 |
| ▸ | CHRNG | P07510 | 3/20 | 0.47 |
| ▸ | CHRNB1 | P11230 | 3/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10099849 | 0.87 | LCK (0.62) | LCK | |
| SCHEMBL23668330 | 0.86 | TRPV1 (0.57) | ITGB3ITGA2BLCKTRPV1HSD17B10 | |
| SCHEMBL10099904 | 0.84 | ALOX15 (0.54) | ITGB3ITGA2BCHRNDGRIA1CHRNA1 | |
| SCHEMBL15711987 | 0.83 | ALOX15 (0.53) | ITGB3ITGA2BCHRNDGRIA1CHRNA1 | |
| SCHEMBL15711971 | 0.82 | LCK (0.49) | LCKTRPV1HSD17B10MEN1MAPT | |
| SCHEMBL8004837 | 0.82 | LCK (0.49) | LCKTRPV1HSD17B10MEN1MAPT | |
| SCHEMBL15711980 | 0.82 | ALOX15 (0.52) | ITGB3ITGA2BCHRNDGRIA1CHRNA1 | |
| SCHEMBL10099894 | 0.82 | CA1 (0.46) | ITGB3ITGA2BLCKGRIA1TRPV1 | |
| SCHEMBL10099813 | 0.81 | CA1 (0.56) | ITGB3ITGA2BLCKCHRNDHSD17B10 | |
| SCHEMBL10099944 | 0.80 | LCK (0.48) | ITGB3ITGA2BLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722923-B2 | Conjugates for treating neurodegenerative diseases and disorders | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2014-05-13 | — | — | US | disclosed |
| US-8722923-B2 | Conjugates for treating neurodegenerative diseases and disorders | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2014-05-13 | — | — | US | disclosed |
| US-20120277310-A1 | NOVEL CONJUGATES FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | BAR-ILAN UNIVERSITY (IL) | 2012-11-01 | — | — | US | disclosed |
| US-8207369-B2 | Conjugates for treating neurodegenerative diseases and disorders | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2012-06-26 | — | — | US | disclosed |
| US-20110034553-A1 | NOVEL CONJUGATES FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277310-A1 | NOVEL CONJUGATES FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | SLC18A2, GABRB2, SLC6A13 | ITGB3 3514/4885ITGA2B 2364/4885LCK 3607/4885 |
| US-20110034553-A1 | NOVEL CONJUGATES FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | SLC18A2, SNCA, SLC6A13 | ITGB3 3970/4885ITGA2B 2825/4885LCK 2796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.